Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.63), $0.03 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $3.02 million versus the consensus estimate of $2.3 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.